Poxel SA raises 17.7m through capital increase
Metabolic disease specialist Poxel SA has announced a private placement of 2,358,483 new ordinary shares at 0.02 per share reserved to specified investors.
British scientists start Phase II on COVID-19 vaccine
Researchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers.
New algorithm predicts rheumatoid arthritis
Based on genetic data, a new diagnostic algorithm can differentiate between five different rheumatic diseases.
SARS-CoV2 antibody tests: not suited for individual diagnosis?
An international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses.
Vaccine to protect from any viral infection
Two companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.
Abivax bags 36m fund for COVID-19 programme
French Abivax SA has received a 36m non-dilutive funding from Bpifrance for its ABX464 Covid-19 programme.
4Teen4s DPP3 predicts burn mortality
4TEEN4 Pharmaceuticals GmbH published data suggesting that high plasma levels of dipeptidyl peptidase 3 were indicative for upcoming multiple organ failure in burn patients.
S-Protein: Glycosylation pattern revealed
British researchers have deciphered the glycosylation pattern of the viral spike protein of SARS-CoV-2 laying the foundation for vaccine development.
Newron terminates sarizotan development in Rett syndrome
Newron Pharmaceuticals S.p.A.s Sarizotan failed to meet efficacy endpoints in the Phase III STARS study.
Bone Therapeutics bags 11m
Belgian Bone Therapeutics SA has secured 11m to foster development of its late stage pipeline candidates.